Indeed, our data from breast cancer patients support this notion, since only in tumors expressing high Pin1 levels the presence of TP53 missense mutations was associated to a worse clinical outcome with reduced overall survival and early development of metastases. The gene discussed is TP53; the disease is breast cancer.